{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/reb-requirements-and-reporting-timelines”
},
“@id”: “https://www.clinicalstudies.in/reb-requirements-and-reporting-timelines”,
“headline”: “SOP for REB Requirements and Reporting Timelines”,
“name”: “SOP for REB Requirements and Reporting Timelines”,
“description”: “Comprehensive SOP describing Research Ethics Board submission and reporting requirements, including initial submissions, continuing reviews, amendments, safety updates, and communication logs to ensure ethics oversight compliance.”,
“keywords”: “REB requirements SOP, ethics board reporting timelines, REB submission SOP, REB approval workflow, ethics compliance Canada, investigator responsibilities REB, trial amendments ethics board, REB notification procedures, protocol approval SOP, REB communication log, safety reporting REB, informed consent REB review, site initiation ethics board, REB correspondence SOP, REB oversight compliance, ethics committee reporting SOP, REB inspection readiness, REB documentation retention, REB approvals and renewals, SOP for clinical research ethics, REB report deadlines, REB continuing review SOP, REB communication management, trial governance SOP ethics, REB sponsor obligations”,
“articleSection”: “Standard Operating Procedure”,
“datePublished”: “2025-08-28”,
“dateModified”: “2025-08-28”,
“author”: { “@type”: “Organization”, “name”: “Clinicalstudies.in” },
“publisher”: {
“@type”: “Organization”,
“name”: “Clinicalstudies.in”,
“logo”: { “@type”: “ImageObject”, “url”: “https://www.clinicalstudies.in/logo.png” }
}
}

REB Requirements and Reporting Timelines SOP

Purpose

This SOP defines the process for submitting documents, obtaining approvals, and reporting to Research Ethics Boards (REBs) to ensure compliance with Division 5 and ICH-GCP requirements. It establishes timelines, documentation standards, and communication pathways to safeguard participant rights and maintain regulatory oversight throughout the clinical trial lifecycle.

Scope

This SOP applies to all REB submissions related to clinical trials sponsored or overseen by the organization. It covers initial submissions, continuing reviews, amendments, safety updates, annual renewals, study termination, and urgent notifications (e.g., protocol deviations impacting subject safety). It is applicable to investigators, site staff, sponsors, regulatory affairs, and clinical research teams operating in compliance with GCP.

Responsibilities

• Principal Investigator (PI): Submits initial and ongoing documentation to the REB, responds to REB queries, and ensures site staff compliance.
• Clinical Research Coordinator (CRC): Prepares submissions, maintains correspondence logs, and tracks timelines for continuing reviews and renewals.
• Regulatory Affairs (RA): Provides regulatory documentation, ensures alignment of REB submissions with CTA dossier, and files acknowledgments in TMF.
• Sponsor/Clinical Project Manager: Oversees REB submission strategy across multiple sites, monitors compliance with timelines, and supports corrective actions.
• Quality Assurance (QA): Audits REB submission packages and correspondence to ensure completeness, accuracy, and inspection readiness.

Accountability

The Principal Investigator is accountable for ensuring timely submission of ethics documents and adherence to REB reporting requirements. The Head of Clinical Research is accountable for oversight and compliance monitoring across studies.

Procedure

1. Initial REB Submission

1. Compile protocol, Investigator’s Brochure (IB), informed consent forms (ICFs), recruitment materials, and relevant safety data.
2. Submit documentation to REB prior to trial initiation and maintain an indexed REB submission file.
3. Record REB approval number, validity dates, and conditions of approval in REB Approval Log.

2. Amendments

1. Submit substantial protocol amendments, revised ICFs, and updated safety data to REB before implementation, unless urgent safety measures are required.
2. Maintain Amendment Log tracking submission dates, approvals, and site-level implementation status.

3. Continuing Review and Renewals

1. Prepare annual progress reports summarizing enrollment, safety events, deviations, and benefit-risk updates.
2. Submit renewal packages at least 30 days before REB approval expiry to ensure uninterrupted trial conduct.

4. Safety Reporting

1. Report unanticipated problems involving risks to participants to REB within 7 days of awareness.
2. Submit expedited reports for SUSARs and periodic updates summarizing safety data.

5. Study Closure

1. Submit final report including enrollment summary, outcomes, and CSR reference to REB after trial completion or early termination.
2. Ensure documentation of REB closure acknowledgment in TMF and ISF.

6. Documentation and Record-Keeping

1. Maintain REB Submission Log, Amendment Log, Safety Reporting Log, and Communication Log in TMF.
2. Archive all REB approvals, correspondence, and supporting documents per retention timelines.

Abbreviations

• REB: Research Ethics Board
• PI: Principal Investigator
• CRC: Clinical Research Coordinator
• CTA: Clinical Trial Application
• CSR: Clinical Study Report
• SUSAR: Suspected Unexpected Serious Adverse Reaction
• TMF: Trial Master File
• QA: Quality Assurance

Documents

1. REB Submission Log (Annexure-1)
2. Amendment Log (Annexure-2)
3. REB Communication Log (Annexure-3)

References

• Health Canada — Clinical Trial Guidance
• Food and Drug Regulations — Division 5
• ICH E6(R2) Good Clinical Practice
• Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans

Version: 1.0

Approval

Annexures

Annexure-1: REB Submission Log

Annexure-2: Amendment Log

Annexure-3: REB Communication Log

Revision History

For more SOPs visit: Pharma SOP.

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sae-dsur-reporting-health-canada”
},
“@id”: “https://www.clinicalstudies.in/sae-dsur-reporting-health-canada”,
“headline”: “SOP for SAE and DSUR Reporting to Health Canada”,
“name”: “SOP for SAE and DSUR Reporting to Health Canada”,
“description”: “Comprehensive SOP defining processes, timelines, and responsibilities for reporting Serious Adverse Events (SAEs), Suspected Unexpected Serious Adverse Reactions (SUSARs), and Development Safety Update Reports (DSURs) to Health Canada.”,
“keywords”: “SAE reporting Health Canada, SUSAR reporting Canada, DSUR submission SOP, expedited safety reporting timelines, pharmacovigilance SOP Canada, SAE case processing, SUSAR compliance Division 5, DSUR regulatory submission Canada, safety reporting sponsor obligations, clinical safety narrative Canada, Health Canada pharmacovigilance requirements, safety reporting workflow SOP, regulatory safety communication Canada, SAE SUSAR PV compliance, annual safety update SOP, DSUR preparation Canada, safety case management SOP, SAE report timelines Canada, inspection readiness PV Canada, pharmacovigilance documentation SOP, safety reporting to regulators Canada, Division 5 safety oversight, SAE report log SOP, DSUR archival requirements, sponsor safety responsibilities”,
“articleSection”: “Standard Operating Procedure”,
“datePublished”: “2025-08-28”,
“dateModified”: “2025-08-28”,
“author”: { “@type”: “Organization”, “name”: “Clinicalstudies.in” },
“publisher”: {
“@type”: “Organization”,
“name”: “Clinicalstudies.in”,
“logo”: { “@type”: “ImageObject”, “url”: “https://www.clinicalstudies.in/logo.png” }
}
}

SAE and DSUR Reporting SOP

Purpose

The purpose of this SOP is to establish clear, regulatory-compliant processes for the identification, assessment, documentation, and reporting of Serious Adverse Events (SAEs), Suspected Unexpected Serious Adverse Reactions (SUSARs), and Development Safety Update Reports (DSURs) to Health Canada. It ensures timely communication, protects subject safety, maintains sponsor obligations under Division 5 of the Food and Drug Regulations, and aligns with ICH-GCP and ICH E2A/E2F guidelines.

Scope

This SOP applies to all interventional clinical trials sponsored or managed by the organization that involve investigational products submitted to Health Canada under a Clinical Trial Application (CTA). It applies to sponsor pharmacovigilance (PV), clinical research, regulatory affairs, investigators, and site staff responsible for adverse event capture, documentation, and reporting.

Responsibilities

• Principal Investigator (PI): Ensures all SAEs are documented and reported to the sponsor within 24 hours of awareness, provides causality assessment, and supports follow-up requests.
• Clinical Research Coordinator (CRC): Assists in SAE data collection, verifies source records, and maintains SAE site files.
• Pharmacovigilance (PV) Team: Performs medical review, causality assessment, prepares case narratives, and submits expedited reports to Health Canada.
• Regulatory Affairs (RA): Coordinates DSUR preparation, ensures timely submission, and files acknowledgments in the TMF.
• Quality Assurance (QA): Audits SAE/SUSAR/DSUR processes and verifies compliance with SOP and regulations.

Accountability

The Sponsor’s Qualified Safety Officer is accountable for ensuring all expedited reports and DSURs are submitted within Health Canada timelines. The Head of Clinical Research is accountable for oversight of compliance across all active trials.

Procedure

1. SAE Reporting Workflow

1. All SAEs must be recorded on the SAE Report Form within 24 hours of investigator awareness.
2. The PI must assess severity, causality, and expectedness based on the Investigator’s Brochure or Reference Safety Information (RSI).
3. Forward SAE documentation to sponsor PV team and REB as required.
4. File source documentation and completed SAE forms in Investigator Site File (ISF).

2. SUSAR Expedited Reporting

1. Fatal or life-threatening SUSARs: Report to Health Canada within 7 calendar days, followed by a complete report within 8 additional days.
2. All other SUSARs: Report within 15 calendar days of sponsor awareness.
3. Submissions must use ICH E2B format through Health Canada electronic gateway with certified translation if required.
4. Maintain SUSAR Submission Log with case ID, subject ID, event, submission date, and acknowledgment.

3. DSUR Submission

1. Prepare annual DSUR covering cumulative safety data, case listings, signal analyses, and benefit-risk evaluations.
2. Submit DSUR in CTD/eCTD format within 60 days of the data lock point.
3. Provide copies to REBs as required by institutional policies.
4. File submission receipts, acknowledgments, and DSUR archival copies in the TMF.

4. Documentation and Record-Keeping

1. Maintain SAE Case Files, SUSAR Submission Logs, and DSUR Submission Logs in TMF.
2. Archive safety documents for minimum of 25 years or until product registration is completed, whichever is longer.
3. Ensure audit trails are complete and ALCOA+ principles are met.

5. Communication with Health Canada

1. All RFIs from Health Canada must be acknowledged within 2 working days.
2. Assign responsibility to PV/RA staff for drafting responses, reviewed by QA prior to submission.
3. Document all communications in the Regulatory Communication Log.

Abbreviations

• SAE: Serious Adverse Event
• SUSAR: Suspected Unexpected Serious Adverse Reaction
• DSUR: Development Safety Update Report
• REB: Research Ethics Board
• PV: Pharmacovigilance
• RA: Regulatory Affairs
• QA: Quality Assurance
• TMF: Trial Master File
• RSI: Reference Safety Information

Documents

1. SAE Reporting Form (Annexure-1)
2. SUSAR Submission Log (Annexure-2)
3. DSUR Submission Log (Annexure-3)

References

• Health Canada — Clinical Trial Guidance
• Food and Drug Regulations, Part C, Division 5
• ICH E2A: Clinical Safety Data Management
• ICH E2F: Development Safety Update Report

Version: 1.0

Approval

Annexures

Annexure-1: SAE Reporting Form

Annexure-2: SUSAR Submission Log

Annexure-3: DSUR Submission Log

Revision History

For more SOPs visit: Pharma SOP.

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/bilingual-documentation-expectations”
},
“@id”: “https://www.clinicalstudies.in/bilingual-documentation-expectations”,
“headline”: “SOP for Bilingual Documentation Expectations”,
“name”: “SOP for Bilingual Documentation Expectations”,
“description”: “Detailed SOP for preparing, reviewing, and controlling bilingual (English and French) documents such as ICFs, IBs, safety narratives, and regulatory submissions, aligned with Health Canada and ICH-GCP.”,
“keywords”: “bilingual documentation SOP, translation quality assurance, English French clinical trial documents, informed consent bilingual Canada, bilingual investigator brochures, REB submission requirements, CTA bilingual dossier, translation certification SOP, bilingual patient information sheets, clinical trial bilingual communication, bilingual safety narratives, Health Canada document compliance, sponsor responsibilities bilingual docs, bilingual protocol amendments, bilingual subject materials, bilingual trial forms Canada, translation verification SOP, inspection readiness bilingual documents, bilingual trial governance, REB bilingual reporting, bilingual ICF comprehension, bilingual archiving SOP, bilingual ethics documents, bilingual trial master file, Health Canada bilingual guidance”,
“articleSection”: “Standard Operating Procedure”,
“datePublished”: “2025-08-28”,
“dateModified”: “2025-08-28”,
“author”: { “@type”: “Organization”, “name”: “Clinicalstudies.in” },
“publisher”: {
“@type”: “Organization”,
“name”: “Clinicalstudies.in”,
“logo”: { “@type”: “ImageObject”, “url”: “https://www.clinicalstudies.in/logo.png” }
}
}

Bilingual Documentation Expectations SOP

Purpose

This SOP defines the processes for preparing, translating, verifying, and controlling bilingual (English and French) documentation used in clinical trials. It ensures compliance with Health Canada Division 5, ICH-GCP, and REB requirements, guaranteeing that participants receive understandable and accurate information while sponsors maintain regulatory compliance and inspection readiness.

Scope

This SOP applies to all sponsor, CRO, and investigator site personnel involved in preparing bilingual documentation for clinical trials. It includes informed consent forms (ICFs), patient information sheets, Investigator’s Brochures (IBs), Clinical Trial Applications (CTAs), safety narratives, regulatory correspondence, and ethics submissions. It covers initial submissions, amendments, safety updates, and final reports.

Responsibilities

• Clinical Research Department: Ensures bilingual documentation is created, reviewed, and filed in the TMF.
• Regulatory Affairs (RA): Confirms CTAs and amendments contain certified English and French versions as required.
• Principal Investigator (PI): Provides bilingual ICFs to participants and ensures comprehension during the consent process.
• Translation Vendor/Language Specialists: Perform certified translations, maintain audit trails, and issue certificates of accuracy.
• Quality Assurance (QA): Audits bilingual documentation processes and verifies compliance with regulatory and ethical requirements.

Accountability

The Head of Clinical Research holds accountability for ensuring bilingual documents meet Health Canada and REB requirements. PIs are accountable for ensuring participants receive understandable bilingual consent materials before trial enrollment.

Procedure

1. Identification of Required Bilingual Documents

1. Identify all subject-facing and regulatory documents requiring bilingual versions (ICFs, IBs, patient leaflets, safety updates).
2. Maintain a Translation Requirement Log in the TMF.

2. Translation and Verification

1. Engage certified translators with medical expertise.
2. Perform back-translation of critical subject-facing materials (e.g., ICFs, safety narratives).
3. Document discrepancies between forward and back translations and resolve prior to finalization.

3. Quality Review and Certification

1. Obtain Certificates of Translation Accuracy from vendors for all finalized translations.
2. Regulatory Affairs confirms alignment between English and French versions prior to submission.
3. File all certificates and QA reviews in the TMF.

4. Submissions and Approvals

1. Include bilingual documents in CTA packages submitted to Health Canada.
2. Ensure REB submissions include both English and French ICFs for review.
3. Confirm acknowledgment and approval letters are archived in both ISF and TMF.

5. Site-Level Use

1. Provide participants with bilingual ICFs at enrollment and confirm understanding using comprehension checklists.
2. Ensure bilingual documentation is readily available at sites for inspection.

6. Documentation and Archiving

1. Maintain Translation Requirement Logs, Certificates of Translation, and QA verification logs in the TMF.
2. Archive bilingual versions of all essential documents for at least 25 years or until marketing authorization is complete.

Abbreviations

• CTA: Clinical Trial Application
• GCP: Good Clinical Practice
• ICF: Informed Consent Form
• IB: Investigator’s Brochure
• QA: Quality Assurance
• REB: Research Ethics Board
• TMF: Trial Master File

Documents

1. Translation Requirement Log (Annexure-1)
2. Certificate of Translation Accuracy (Annexure-2)
3. Bilingual Consent Comprehension Checklist (Annexure-3)

References

• Health Canada — Clinical Trial Guidance
• Food and Drug Regulations, Part C, Division 5
• ICH E6(R2) Good Clinical Practice
• Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans

Version: 1.0

Approval

Annexures

Annexure-1: Translation Requirement Log

Annexure-2: Certificate of Translation Accuracy

Annexure-3: Bilingual Consent Comprehension Checklist

Revision History

For more SOPs visit: Pharma SOP.

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-division-5-cta-submissions-and-lifecycle-events-health-canada”
},
“headline”: “SOP for Division 5 CTA Submissions and Lifecycle Events (Health Canada)”,
“description”: “This SOP defines the procedures for preparing, submitting, and managing Clinical Trial Applications (CTAs) and lifecycle events under Division 5 of the Canadian Food and Drug Regulations. It ensures compliance with Health Canada requirements, covering initial submissions, amendments, notifications, and end-of-trial obligations.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-27”,
“dateModified”: “2025-08-27”
}

Standard Operating Procedure for Division 5 CTA Submissions and Lifecycle Events (Health Canada)

Purpose

The purpose of this SOP is to establish procedures for preparing, submitting, and managing Clinical Trial Applications (CTAs) and related lifecycle events in Canada under Division 5 of the Food and Drug Regulations. It provides guidance for sponsors, CROs, and investigators to ensure compliance with Health Canada requirements, safeguard subject safety, and maintain regulatory transparency. This SOP addresses initial CTA submission, amendments, notifications, withdrawal, and end-of-trial reporting.

Scope

This SOP applies to sponsors, CROs, regulatory affairs professionals, investigators, data managers, QA personnel, and pharmacovigilance (PV) staff involved in clinical trial submissions in Canada. It covers trials for pharmaceuticals, biologics, radiopharmaceuticals, advanced therapies, and other investigational medicinal products regulated by Health Canada under Division 5. The SOP also outlines inspection readiness practices specific to Canadian requirements.

Responsibilities

• Sponsor: Ensures accurate and timely submission of CTAs and lifecycle updates to Health Canada.
• CRO: Assists in compilation, quality control, and submission of CTA documents.
• Investigator: Provides site-specific documents, such as qualifications, consent forms, and REB approvals.
• Regulatory Affairs: Coordinates CTA submissions, maintains submission logs, and communicates with Health Canada.
• PV Department: Manages safety data and ensures timely submission of safety reports and amendments.
• QA: Audits CTA documents and lifecycle event submissions for compliance.

Accountability

The Sponsor’s Head of Regulatory Affairs is accountable for ensuring that CTA submissions and lifecycle management activities comply with Health Canada Division 5 requirements and timelines.

Procedure

1. Initial CTA Preparation
1.1 Assemble core CTA package: protocol, Investigator’s Brochure (IB), Chemistry and Manufacturing Information (CMC), Informed Consent Forms (ICFs), and supporting appendices.
1.2 Ensure documents comply with Health Canada’s Guidance for Clinical Trial Sponsors.
1.3 Perform internal QA review prior to submission.
1.4 Log all documents in CTA Preparation Log (Annexure-1).

2. Submission to Health Canada
2.1 Submit CTA through the appropriate Health Canada channel (currently via electronic Common Technical Document, eCTD).
2.2 Acknowledge receipt of confirmation and CTA Control Number from Health Canada.
2.3 Document in CTA Submission Log (Annexure-2).

3. Review and Queries
3.1 Monitor Health Canada feedback during the 30-day review period.
3.2 Respond to Requests for Clarification (RFCs) within specified deadlines.
3.3 Maintain a CTA Query Response Log (Annexure-3).

4. CTA Amendments
4.1 Classify amendments as substantial or administrative.
4.2 Substantial amendments include changes to study design, patient population, or safety monitoring.
4.3 Submit amendments with revised documents to Health Canada.
4.4 Track approvals in Amendment Log (Annexure-4).

5. Notifications
5.1 Notify Health Canada of protocol deviations, urgent safety measures, or investigator changes within defined timelines.
5.2 Submit annual updates summarizing ongoing trial progress.
5.3 Record in Notification Log (Annexure-5).

6. End-of-Trial Reporting
6.1 Submit an End-of-Trial Notification within 30 days of study closure.
6.2 Provide Clinical Study Report (CSR) within 12 months.
6.3 Document submissions in End-of-Trial Log (Annexure-6).

7. Withdrawal of CTA
7.1 Sponsors may withdraw CTAs voluntarily.
7.2 Submit withdrawal request with justification to Health Canada.
7.3 Document in Withdrawal Log (Annexure-7).

8. Safety Reporting Obligations
8.1 Submit expedited reports for Serious Unexpected Adverse Drug Reactions (SUSARs).
8.2 Report annual Development Safety Update Reports (DSURs).
8.3 Record in Safety Reporting Log (Annexure-8).

9. Inspection Readiness
9.1 Maintain inspection-ready archives for CTA submissions.
9.2 Conduct mock inspections annually to verify compliance.
9.3 Record findings in Inspection Readiness Log (Annexure-9).

10. Archiving and Retention
10.1 Archive CTA documents securely for at least 25 years or as required by Health Canada.
10.2 Implement both paper and electronic archiving with validated systems.
10.3 Record in Archiving Log (Annexure-10).

Abbreviations

• SOP: Standard Operating Procedure
• CTA: Clinical Trial Application
• REB: Research Ethics Board
• QA: Quality Assurance
• PV: Pharmacovigilance
• DSUR: Development Safety Update Report
• SUSAR: Suspected Unexpected Serious Adverse Reaction
• CSR: Clinical Study Report
• eCTD: electronic Common Technical Document
• CMC: Chemistry and Manufacturing Information

Documents

1. CTA Preparation Log (Annexure-1)
2. CTA Submission Log (Annexure-2)
3. CTA Query Response Log (Annexure-3)
4. Amendment Log (Annexure-4)
5. Notification Log (Annexure-5)
6. End-of-Trial Log (Annexure-6)
7. Withdrawal Log (Annexure-7)
8. Safety Reporting Log (Annexure-8)
9. Inspection Readiness Log (Annexure-9)
10. Archiving Log (Annexure-10)

References

• Health Canada – Clinical Trials
• Health Canada – Guidance Documents
• ICH GCP Guidelines

Version: 1.0

Approval Section

Annexures

Annexure-1: CTA Preparation Log

Annexure-2: CTA Submission Log

Annexure-3: CTA Query Response Log

Annexure-4: Amendment Log

Annexure-5: Notification Log

Annexure-6: End-of-Trial Log

Annexure-7: Withdrawal Log

Annexure-8: Safety Reporting Log

Annexure-9: Inspection Readiness Log

Annexure-10: Archiving Log

Revision History

For more SOPs visit: Pharma SOP